DOI:
10.1055/s-00000142
Frauenheilkunde up2date
LinksClose Window
References
Ismael G, Hegg R, Muehlbauer S et al.
Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in
patients with HER2-positive, clinical stage I–III breast cancer (HannaH study):
a phase 3, open-label, multicentre, randomised trial.
Lancet Oncology 2012;
13: 869-878
We do not assume any responsibility for the contents of the web pages of other providers.